JP2006527245A - 磁性ナノ粒子 - Google Patents
磁性ナノ粒子 Download PDFInfo
- Publication number
- JP2006527245A JP2006527245A JP2006516378A JP2006516378A JP2006527245A JP 2006527245 A JP2006527245 A JP 2006527245A JP 2006516378 A JP2006516378 A JP 2006516378A JP 2006516378 A JP2006516378 A JP 2006516378A JP 2006527245 A JP2006527245 A JP 2006527245A
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- magnetic
- ligand
- nanoparticle
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1845—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carbohydrate (monosaccharides, discacharides)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Ceramic Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Soft Magnetic Materials (AREA)
- Hard Magnetic Materials (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paints Or Removers (AREA)
Abstract
Description
(a)配位子の硫化物誘導体を合成する段階と;
(b)粒子を製造するための還元剤の存在下で、硫化物誘導体配位子を、HAuCl4(テトラクロロ金酸)及び任意でコア内に鉄原子が存在する第二鉄塩と反応する段階と ;を備える。好適な鉄塩はFeCl3である。
不動態化金属、又は、不動態化金属及び磁気金属を備えたコアであって、複数の配位子に共有結合されたコアを有するここに規定したナノ粒子を、一又は二以上の候補化合物に接触させる段階と;
候補化合物が配位子に結合するか否かを検出する段階と;を備える。
Lex−GNP Ley−GNP STn−GNP
Glogo−H−GNP Gg3−GNP Gluco−GNP
Malto−GNP Lacto−GNP Man−GNP
ナノ粒子はコア粒子に結合した配位子に対して抗体応答を生ずるキャリアとして使用してもよい。これらの抗体は従来標準の技術を用いて変成できる。ここにはじめて例示するものと類似の抗体も公知の方法に関連してここに教示したものを用いて生成できる。これらの抗体を製造する方法は、ナノ粒子を用いてほ乳類(例えば、マウス、ラット、うさぎ、馬、やぎ、羊、又は猿)に免疫性を与える(免疫化する)ことを含む。抗体は従来公知の種々の技術のいずれを用いて、好ましくは抗体の対象の抗原への結合を用いることによってスクリーニングして免疫性が与えられた動物から得られてもよい。動物から、抗体及び/又は細胞生成抗体を分離することは、動物の犠牲の段階を伴ってもよい。
例1−Au−Feナノ粒子
配位子に共有結合した磁気糖ナノ粒子を合成する方法を見出した。例として、2つの重要なオリゴ糖のチオール誘導ネオ複合糖質1及び2、非抗原性二糖マルトース(Glcα(1→4)Glcβ1−OR)、及び、抗原性ラクトース(Galβ(1→4)Galβ1−OR)を、インサーチュー磁性ナノ粒子を機能化するように準備した(図3,スキーム1)。ジスルフィド1及び2の合成は、都合よく保護されたマルトース及びラクトース誘導体を、11-アセチルチオ-アンデカノール(11-acetylthio-undecanol)、11-アセチルチオ-3,6,9-トリオキサ-アンデカノール(11-acetylthio-3,6,9-trioxa-undecanol)のそれぞを用いてグリコシド化することによって実施した[12]。いずれのリンカーも、材料全体の特性における疎水性若しくは親水性の影響をテストするために用いられてきた。化合物1及び2はジスルフィドの形で分離し、金−鉄保護糖ナノ粒子の準備のためにこの形で用いた。水溶性糖ナノ粒子1−AuFe(マルト(malto)−AuFe)及び2−AuFe(ラクト−AuFe)はワンポット合成を用いてメタノール/水混合物において得た。1:4の比のFeCl3及びHAuCl4をジスルフィド1又は2の存在下でNaBH4を用いて還元した。金属コアをネオ複合糖質単層で保護することにより、高安定性でバイオ機能化ナノクラスターとなる。これらは遠心濾過によって精製され、1H−NMR、UV−vis、ICP、TEM、EDX及びSQUIDによってキャラクタライズされてきた。
マルトCu11SauFe:水(0.5mL)にFeCl3(2mg;0.013mmol;0.25当量)が溶解した溶液を、MeOH(11.5mL)にジスフフィド1(80mg;0.075mol;3当量)を溶解した溶液に入れ、次いで、水(2mL)にHauCl4(17mg;0.05mmol;1当量)が溶解した溶液を入れた。次いで、NaBH41M(52mg;1.38mmol;27.5当量)を高速撹拌しながら少量加えた。生成した黒い懸濁液をさらに2時間撹拌し、真空中で溶媒を除去した。糖ナノ粒子はMeOHで不溶性であるが、水には可溶である。
精製を遠心濾過によって実施した。粗生成物を水(〜15mL)NANOpureで溶解し、溶液を遠心濾過器(CENTRIPLUS YM30,MICROCON,MWCO=30000)内にロードし、遠心力(3000×g,40分)を印加した。黒っぽい糖ナノ粒子残留物をMeOH及び水で洗い、開始材料がもはや薄層クロマトグラフィ(TLC)で検出できなくなるまで複数回繰り返した。残留物を水に溶解し、複数回遠心力をかけて、不溶性材料を除去した。透明な溶液を凍結乾燥し、得られた生成物は塩及び開始材料がなかった(1H及び23NaNMRスペクトロスコピ−においてジスルフィド及びNa+からの信号がなかった)。
サンプルのTEM検査を200kV(フィリップス社のCM200マイクロスコープ)で実施した。Au/Fe糖ナノ粒子の水溶液の一滴(20μL)をカーボン膜で被覆された銅グリッド上に置いた。グリッドは室温で数時間空気中で乾燥した。Au/Feクラスターの粒子サイズ分布を、自動イメージアナライザーを用いて複数の顕微鏡写真から評価した。EDX分析は顕微鏡に取り付けたフィリップス社のDX4装置で実施した。ICP分析はPEC−009プロトコルに従ってアグルクエムS.L.によって実施した。UVスペクトルをUV/visパーキンエルマーラムダ12分光光度計によって得た。1H−NMRスペクトルはブルーカーDRX−500スペクトロメータによって得た。化学シフトをD2Oに対してppm(δ)で与えられている。
ICP:0.27%Fe
UV(H2O):λ=500nm、表面プラズモン共鳴1H−NMR(500MHz、D2O)δ:5.32(brd、1H、H−1’)、4.37(brd、1H、H−1)、4.00−3.30(m、13H)、2.70(s,2H,CH2S)、1.85−1.20(m、17H)
ICP:2.81%Fe
UV(H2O):λ=500nm、表面プラズモン共鳴1H−NMR(500MHz、D2O)δ:4.49(brd、1H、H−1’)、4.40(brd、1H、H−1)、4.10−3.30(m、23H)、2.92(m、0.5H)
異なる糖質分子の自己組織化単層(SAM)で安定化された水溶性金糖ナノ粒子(GNP)は、過剰なチオール誘導ネオ複合糖質の存在下で、水溶液中に金属塩前駆体の化学的還元によって準備した。サンプル準備手順では、出発として、金属クラスタが同時に保護されかつ有機分子で機能化された金GNPを生成するペナデらによるもの[11]、[19]を用いた。Au−S共有結合の形成は、その成長を妨害する金属クラスター(コア直径〜2nm)を分離し、溶液中においてナノクラスター上で大きな安定性を付与する。
四塩化金酸(HAuCl4、0.018mmol)及び過剰なジスルフィドネオ複合糖質(0.2mmol)の水溶液を質問で水素化ホウ素ナトリウム(NaBH4,22当量)で還元した。茶色の懸濁液が直ちに形成した。懸濁液を約2時間振り、次いで、溶媒を除去し、糖ナノ粒子(GNP)を水で洗いかつ遠心濾過(CENTRIPLUS、Mr30000、1時間、3000xg)することによって精製した。フィルタにおける残留物は水に溶解し、凍結乾燥した。GNPは透過型電子顕微鏡(TEM)、1HNMR、UV−可視スペクトロスコピー、導結合高周波プラズマ(ICP)、及び元素分析によってキャラクタライズした。TEM:平均直径;Au原子数、それぞれ1.5nm、79個。UV−VIS(H2O):λ=520nm。ICP:28%Au。(C23H43O11S)nAun(n=79)について計算した元素分析:C 38.18;H 5.98;S 4.40;Au 27.18。見つかった:C 39.5;H 6.07;Au 28.0。
金糖ナノ粒子(GNP)はGd(III)及び他のランタノイドに複合されて新しいコントラスト剤を提供する。GNPに存在するネオ複合糖質配位子(60から100分子)はキレート部分である。
ここに記載した参考文献はすべて参考として組み込まれている。
[1] Niemeyer, C.M. Angew. Chem. Int. Ed. 2001, 40, 4128-4158.
[2] Bergemann, C.; Mueller-Schulte, D.; Oster, J.; Brassard, L.; Luebbe, A.S. J. Magn. Magn. Mater. 1999, 194, 45.
[3] Whitesides, G.M.; Kazlauskas R.J.; I Josephson L. Trends Biotechno1. 1983, 1, 144-148.
[4] Sun, S.; Murray, C.B.; Weller, D.; Folksm, L.;. Moser, A. Science 2000, 287, 1989.
[5] a) Shafi, K.V.P.M.; Gedanken, A.; Prozorov, R. Adv. Mater. 1998, 10, 590-593. b) Fried, T.; Shemer, G.; Markovich, G. Adv. Mater. 2001, 13, 1158-1161. c) Moumen, N.; Veillet, P.; Pileni, M.P.. J. Magn. Magn. Mater. 1995, 149, 67-71.
[6] Park, S.-J.; Kin, S.; Lee, S.,. Khim, a.G.,I Chart K.; Hyeon, T. J. Am. Chem. Soc. 2000, 122, 8581-8282.
[7] a) Suslick, K.S.; Fangr M.I. Hyeonr T. J. Am. Chem. Soc. 1996, 118,11960-11961. b) Sun, S.; ZengH. J. Am. Chem. Soc 2002, 124, 8204-8205. c) Guo, Q.; Teng' X.; Rahman, S.; Yangr H. J. Am. Chem. Soc. 2003, 125, 630-631.
[8] Sun, S.; Anders, S.; Hamann H.F.; Thiele,J.-U.; BaglinI J.E.E.; ThomsonI T.; Fullerton, E.E.; Hurray,C.B.; Terrisr B.D. J. Am. Chem. Soc. 2002, 124, 2884-2885.
[9] a) Josephson, L.; Tung, C.-H.; Moore, A.; Weissleder, R. Bioconjugate Chem. 1999, 10, 186-191. b) Lewin, M.; Carlesso, N.; Tung, C.-H.; Tang, X.-W; Cory, D.; Scadden, D.T.; Weissleder, R. Nat. Biotechno1. 2000, 18, 410-414.
[10] Josephson, L.; Perez, J.M.; Weissleder, R. Angew.Chem. Int. Ed. 2001, 40, 3204-3206.
[11] de la Fuente, J.M.; Barrientos, A.G.; Rojas, T.C.; Rojo, J.; Canada, J.; Fernandez, A.; Penades, S. Angew. Chem. Int. Ed. 2001, 40, 2257-2261.
[12] Barrientos, A.G.; de la Fuente, J.M.; Rojas, T.C.; Fernandez, A.,. Penades, S. Chem. Eur.J. 2002, 9, 1909-2001.
[13] Hernaiz, M.J.; de la Fuente, J.M.; Barrientos, A.G.; Penades, S. Angew. Chem. Int. Ed. 2002, 41, 1554-1557.
[14] Zhou, W.L.; Carpenter, E.E.; Lin, J.; Kumbhar, A.; Sims, J.; O'Connor, C.J. Eur. Phys. J. D. 2001, 16, 289-292.
[15] Mykhaylyk O.; Cherchenko A.; Ilkin A.; Dudchenko N.; Ruditsa V.; Novoseletz M.; Zozulya Y. J. Magn. Magn. Mater. 2001, 225, 241-247.
[16] Jordan, A.; Scholz, R.,. Wust, P.; Fahling, H.; Felix, R. J. Magn. Magn. Mater. 1999, 201, 413-419.
[17] Josephson, L.; Kircher M.F.; Mahmood, U.; Tang, Y,; Weissleder R. Bioconjugate Chem. 2002, 13, 554-560.
[18] Taton et a1, Science 2000 289..1757-1760.
[19] Barrientos A.G. et a1., Chem. Eur. J. 9, 2003, 1909-1921.
[20] Gambardela, P. et a1, Giant Magnetic Anisotropy of Single Cobalt Atoms and Nanoparticles, Science, 2003, 300, 1130-1133.
[21] Di Felice, R.; Selloni, A.; Molinari, E.; J. Phys. Chem. B., 2003, 107, 1151-1156.
[22] D. Davidovic and M. Tinkham, Phys. Rev. Lett., 1999, 83 (8), 1644-1647.
[23] Vitos, L., Johansson, B., Phys. Rev. B., 2000, 62 (18), R11957.
[24] Villas, I.M.IJ., Chatelain, A., de Beer, W.A., Science, 1994, 265, 1682- 1684.
Claims (65)
- 金属原子のコアを有する磁性ナノ粒子であって、前記コアが複数の配位子に共有結合し、2.5nm以下の直径を有する磁性ナノ粒子。
- 前記コアが不動態化金属原子及び磁性金属原子を含む請求項1に記載の磁性ナノ粒子。
- 前記コアが不動態化金属原子を含む請求項1に記載の磁性ナノ粒子。
- 前記不動態化金属が金、白金、銀又は銅であり、任意の磁性金属が鉄、コバルト又はガドリニウムである請求項2又は3のいずれかに記載の磁性ナノ粒子。
- 前記コアが、Au,Au/Fe,Au/Cu,Au/Gd,Au/Fe/Cu,Au/Fe/Gd,又は、Au/Fe/Cu/Gdの原子からなる請求項1から4のいずれか一項に記載の磁性ナノ粒子。
- 前記磁性金属原子に対する不動態化金属原子の比が約5:0から約2:5である請求項2から5のいずれか一項に記載の磁性ナノ粒子。
- 前記磁性金属原子に対する不動態化金属原子の比が約5:0.1から約5:1である請求項2,4又は5のいずれか一項に記載の磁性ナノ粒子。
- 前記不動態化金属が金であり、磁性金属が鉄である請求項2,4,5又は7のいずれかに記載の磁性ナノ粒子。
- 鉄原子に対する金原子の比は約5:0.1である請求項8に記載の磁性ナノ粒子。
- 鉄原子に対する金原子の比は約5:1である請求項8に記載の磁性ナノ粒子。
- 前記コアがAuのような不動態化金属原子だけを含むときに、コアが2.0nm以下の直径を有する請求項1,2,4又は5のいずれかに記載の磁性ナノ粒子。
- 前記配位子がランタニドを組み込んでいる請求項1から11のいずれか一項に記載の磁性ナノ粒子。
- 前記配位子がガドリニウムを組み込んでいる請求項12に記載の磁性ナノ粒子。
- ナノ粒子がNMR活性原子を備えた請求項1から13のいずれか一項に記載の磁性ナノ粒子。
- 前記NMR活性原子が、Mn+2,Gd+3,Eu+2,Cu+2,V+2,Co+2,Ni+2,Fe+2,Fe+2,又はランタノイド+3である請求項14に記載の磁性ナノ粒子。
- 前記配位子は糖質基を備えた請求項1から15のいずれか一項に記載の磁性ナノ粒子。
- 前記配位子は多糖、オリゴ糖、又は、単糖の基を備えた請求項1から16のいずれか一項に記載の磁性ナノ粒子。
- 前記配位子はグリカノコンジュゲートを備えた請求項1から16のいずれか一項に記載の磁性ナノ粒子。
- 前記グリカノコンジュゲートが糖脂質又は糖タンパク質である請求項18に記載の磁性ナノ粒子。
- 前記配位子がスルフィド基を介してコアに連鎖している請求項1から19のいずれか一項に記載の磁性ナノ粒子。
- ナノ粒子がラベルを備えた請求項1から20のいずれか一項に記載の磁性ナノ粒子。
- 前記ラベルは蛍光性基、放射性同位元素又はNMR活性原子である請求項21に記載の磁性ナノ粒子。
- 前記ナノ粒子がペプチドを備えた請求項1から22のいずれか一項に記載の磁性ナノ粒子。
- 前記ナノ粒子がDNA又はRNAを備えた請求項1から23のいずれか一項に記載の磁性ナノ粒子。
- 前記ナノ粒子が薬剤活性コンポーネントを備えた請求項1から24のいずれか一項に記載の磁性ナノ粒子。
- 前記配位子が細胞上でレセプターと結合できる請求項1から25のいずれか一項に記載の磁性ナノ粒子。
- 前記ナノ粒子が水溶性である請求項1から26のいずれか一項に記載の磁性ナノ粒子。
- 請求項1から27のいずれか一項に記載の一又は二以上のナノ粒子の集団を備えた組成物。
- 異なる配位子基を有する複数のナノ粒子を備えた請求項28に記載の組成物。
- 医療上の治療方法で用いるものであって、請求項1から27のいずれか一項に記載の一又は二以上のナノ粒子の集団を備えた組成物。
- 前記組成物がコロイドである請求項28から30のいずれか一項に記載の組成物。
- 前記ナノ粒子が2nm以下の平均直径を有する請求項31に記載のコロイド。
- 前記ナノ粒子が少なくとも約1年間安定である請求項31又は32のいずれかに記載のコロイド。
- 配位子の投与によって改善する状態の処置のための薬剤を生成するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用。
- 前記配位子が病変を引き起こす糖質媒介相互作用を妨げる請求項34に記載の使用。
- 前記ナノ粒子がこれに結合されて複数の配位子を有し、これによって多価の糖質媒介相互作用を妨げることができる請求項34又は35のいずれかに記載の使用。
- 抗原を用いて患者にワクチンを接種をするための薬剤を生成するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用であって、前記ナノ粒子のコアに連鎖した配位子がその抗原を備えたところの使用。
- 抗原をエンコーディングする核酸を用いて患者に予防接種をするための薬剤を生成するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用であって、前記ナノ粒子のコアに連鎖した配位子がその核酸を備えたところの使用。
- 前記ワクチンが磁場の印加によって投与される請求項37又は38のいずれかに記載の使用。
- 磁気共鳴イメージング用のコントラスト剤を作製するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用。
- 前記コントラスト剤が患者の肺をイメージングする際に使用されるものである請求項40に記載の使用。
- 前記イメージング剤が喘息及び肺気腫の診断若しくは治療で使用されるされるものである請求項41に記載の使用。
- 前記ナノ粒子がガドリニウムを備え、1.0nmのコア直径を有する請求項40から42のいずれか一項に記載の使用。
- 癌治療用の薬剤を生成するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用。
- 癌が腫瘍である請求項44に記載の使用。
- 腫瘍が高周波磁場、又は、赤外線に曝される請求項44又は45のいずれかに記載の使用。
- 前記ナノ粒子が、腫瘍関連抗原又は腫瘍自己分泌因子である配位子を備えた請求項44から46のいずれか一項に記載の使用。
- 前記配位子が糖質である請求項47に記載の使用。
- 癌の治療が転移を阻止することである請求項44から48のいずれか一項に記載の使用。
- 前記配位子が、転移に対する特異性若しくは親和性を有する糖質、ホルモン、DHEA、細胞特定レセプターに結合できるペプチド、トールレセプターを結合するための脂質、又は、転移するメラノーマ細胞に結合するメチレンブルーを備えた請求項49に記載の使用。
- 心筋救済のための薬剤を生成するための請求項1から27のいずれか一項に記載のナノ粒子又は請求項28から33のいずれか一項に記載の組成物の使用
- 請求項1から26のいずれか一項に記載のナノ粒子を作製する方法であって、該ナノ粒子は金原子と任意で鉄原子を含むコアを備え、該コアは複数の配位子に共有連鎖するものである方法において:
(a)配位子のスルフィド誘導体を合成する段階と;
(b)粒子を製造するための還元剤の存在下で、前記スルフィド誘導体配位子を、HAuCl4(テトラクロロ金酸)と任意でコア内に鉄原子が存在する第二鉄塩と反応させる段階と;を備えた方法。 - 段階(b)は、リンカーを有する配位子を誘導する段階を備えた請求項52に記載の方法。
- リンカーがジスルフィドリンカーである請求項53に記載の方法。
- ジスルフィドリンカー基が一般式HO−(CH2)n−S−S−(CH2)m−OHによって表されるものであって、n及びmは独立した1から5の整数である請求項54に記載の方法。
- 前記配位子が保護されたジスルフィドとして誘導される請求項55に記載の方法。
- 前記配位子が糖質の基を備えた請求項52から56のいずれか一項に記載の方法。
- 請求項52から57のいずれか一項に記載の方法によって得られたナノ粒子。
- 糖質と結合パートナーとの相互作用を壊す方法であって、糖質及び結合パートナーを請求項1から27のいずれか一項に記載のナノ粒子に接触させる段階を備え、該ナノ粒子に結合された配位子が糖質と結合パートナーとの相互作用を壊することができる糖質基を備えたものである方法。
- 配位子に結合できる物質をスクリーニングする方法であって、(a)請求項1から27のいずれか一項に記載のナノ粒子を一又は二以上の候補化合物と接触させる段階と、(b)該候補化合物が前記配位子に結合するかどうかを決定する段階と、を備えた方法。
- 配位子に結合できる物質の試料における存在を決定する方法であって、(a)当該物質がナノ粒子の配位子に結合するように、当該試料を請求項1から27のいずれか一項に記載のナノ粒子に接触させる段階と、(b)結合が生ずるか否かを決定する段階と、を備えた方法。
- 前記段階が、結合の存否を物質の存在に関連した病気の状態の診断に相関させる段階をさらに備えた請求項61に記載の方法。
- 前記物質が配位子に結合できる抗体である請求項61又は62のいずれかに記載の方法。
- 糖質媒介相互作用が生ずるか否かを決定する方法であって、(a)糖質媒介相互作用を介して相互作用するようにされた一又は二以上の種を請求項1から27のいずれか一項に記載のナノ粒子に接触させる段階と、(b)ナノ粒子が糖質媒介相互作用を変調するかどうかを決定する段階と、を備えた方法。
- ナノ粒子が核磁気共鳴(NMR)、凝集、透過型電子顕微鏡(TEM)、原子間力顕微鏡(AFM)、表面プラズモン共鳴(SPR)によって検出され、又は、ナノ粒子が銀原子を備えて銀(I)のナノ粒子促進還元を用いて信号増幅によって検出される請求項59から64のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0313259.4 | 2003-06-09 | ||
GBGB0313259.4A GB0313259D0 (en) | 2003-06-09 | 2003-06-09 | Magnetic nanoparticles |
PCT/GB2004/002408 WO2004108165A2 (en) | 2003-06-09 | 2004-06-07 | Magnetic nanoparticles linked to a lingand |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006527245A true JP2006527245A (ja) | 2006-11-30 |
JP5008977B2 JP5008977B2 (ja) | 2012-08-22 |
Family
ID=27589724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006516378A Expired - Fee Related JP5008977B2 (ja) | 2003-06-09 | 2004-06-07 | 磁性ナノ粒子 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8557607B2 (ja) |
EP (3) | EP1631318B1 (ja) |
JP (1) | JP5008977B2 (ja) |
AT (1) | ATE487496T1 (ja) |
AU (1) | AU2004244811B9 (ja) |
CA (1) | CA2528460C (ja) |
DE (1) | DE602004030003D1 (ja) |
DK (1) | DK1631318T3 (ja) |
ES (3) | ES2355728T3 (ja) |
GB (1) | GB0313259D0 (ja) |
HK (1) | HK1168051A1 (ja) |
WO (1) | WO2004108165A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010517287A (ja) * | 2007-01-24 | 2010-05-20 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 作用領域の磁性粒子に影響を与え及び/又はそれらを検出する方法、磁性粒子及び磁性粒子の使用 |
JP2013505728A (ja) * | 2009-09-25 | 2013-02-21 | エヌ3ディー バイオサイエンスィズ,インコーポレイテッド | 細胞を磁性化するための材料及び磁気操作 |
JP2015518874A (ja) * | 2012-06-08 | 2015-07-06 | エスリス ゲーエムベーハーethris GmbH | メッセンジャーrnaの肺送達 |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
JP5398982B2 (ja) * | 2004-05-24 | 2014-01-29 | ミダテック リミテッド | Rnaリガンドを含むナノ粒子 |
JP3912391B2 (ja) * | 2004-05-26 | 2007-05-09 | ソニー株式会社 | 金属磁性ナノ粒子群及びその製造方法 |
KR100604976B1 (ko) * | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | 다작용기 리간드로 안정화된 수용성 나노입자 |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
WO2007015105A2 (en) * | 2005-08-04 | 2007-02-08 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
DE102005042768A1 (de) * | 2005-09-08 | 2007-03-15 | Ludwig-Maximilian-Universität | Magnetfeld-gesteuerter Wirkstofftransfer für die Aerosoltherapie |
CN1772303A (zh) * | 2005-10-25 | 2006-05-17 | 朱宏 | 恶性肿瘤磁热疗用纳米磁粉-抗体靶向药物 |
KR100713745B1 (ko) * | 2006-02-27 | 2007-05-07 | 연세대학교 산학협력단 | 상전이 리간드로 코팅된 수용성 자성 또는 금속 산화물나노입자 및 이의 제조방법 |
JP2007269770A (ja) * | 2006-03-09 | 2007-10-18 | Mitsubishi Chemicals Corp | 機能性磁気超ナノ微粒子及びその用途 |
CA2652759C (en) | 2006-04-13 | 2014-07-08 | Midatech Limited | Nanoparticles for providing immune responses against infectious agents |
KR100803213B1 (ko) * | 2006-06-27 | 2008-02-14 | 삼성전자주식회사 | 패턴된 자기기록매체 및 그 제조방법 |
EP2099496A2 (en) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
CA2591496C (en) | 2006-12-18 | 2014-09-02 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
WO2008098248A2 (en) | 2007-02-09 | 2008-08-14 | Northwestern University | Particles for detecting intracellular targets |
AT503845B1 (de) * | 2007-04-11 | 2008-03-15 | Arc Austrian Res Centers Gmbh | Optische messverfahren zur molekularen detektion anhand von relaxationsmessungen in optisch anisotropen nanopartikeln |
US10118834B2 (en) * | 2007-04-27 | 2018-11-06 | The Regents Of The University Of California | Superparamagnetic colloidal photonic structures |
EP2160464B1 (en) | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8409463B1 (en) | 2007-07-16 | 2013-04-02 | University Of Central Florida Research Foundation, Inc. | Aqueous method for making magnetic iron oxide nanoparticles |
ES2320837B1 (es) | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
DE102007036570A1 (de) * | 2007-08-03 | 2009-02-19 | Siemens Ag | Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests |
US9175015B2 (en) | 2007-08-22 | 2015-11-03 | Colorado School Of Mines | Gold nanoparticle conjugates and uses thereof |
US9057094B1 (en) | 2007-10-25 | 2015-06-16 | University Of Central Florida Research Foundation, Inc. | Nanoparticle-mediated methods for antimicrobial susceptibility testing of bacteria |
US9107858B2 (en) * | 2007-12-05 | 2015-08-18 | Wisconsin Alumni Research Foundation | Dendritic cell targeting compositions and uses thereof |
WO2009075817A1 (en) * | 2007-12-06 | 2009-06-18 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
KR101050401B1 (ko) * | 2008-05-09 | 2011-07-19 | 경북대학교 산학협력단 | 이중 방식 pet/mr 조영제 |
US8968705B2 (en) | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
EP3335705A1 (en) | 2008-11-24 | 2018-06-20 | Northwestern University | Polyvalent rna-nanoparticle compositions |
US20120121717A1 (en) * | 2008-12-30 | 2012-05-17 | Xi'an Goldmag Nanobiotech Co. Ltd | DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2011002760A1 (en) * | 2009-06-30 | 2011-01-06 | Boston Scientific Scimed, Inc. | Biodegradable implant for treating or preventing reperfusion injury |
WO2011008534A1 (en) * | 2009-06-30 | 2011-01-20 | Boston Scientific Scimed, Inc. | Implantable self-powered biodegradable medical device to treat or prevent reperfusion injury |
US20120277283A1 (en) * | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
US20120244205A1 (en) * | 2009-08-25 | 2012-09-27 | The Regents Of The University Of California | Nanotechnological Delivery of Microbicides and Other Substances |
DK2494075T3 (en) | 2009-10-30 | 2018-07-23 | Univ Northwestern | TABLE-MANAGED NANOCONJUGATES |
US8565892B2 (en) | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
US9089512B2 (en) | 2009-12-18 | 2015-07-28 | President And Fellows Of Harvard College | Active scaffolds for on-demand drug and cell delivery |
US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
ES2718303T3 (es) | 2010-06-10 | 2019-07-01 | Midatech Ltd | Nanopartículas que portan péptidos |
WO2011156711A1 (en) | 2010-06-10 | 2011-12-15 | Schobel Alexander M | Nanoparticle film delivery systems |
US8790704B2 (en) * | 2010-06-10 | 2014-07-29 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
ES2706913T3 (es) * | 2010-06-25 | 2019-04-01 | Univ Aston | Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas |
WO2012050810A2 (en) * | 2010-09-29 | 2012-04-19 | The Board Of Trustees Of The University Of Alabama | Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging |
CN102243058B (zh) * | 2011-04-15 | 2013-03-27 | 中国船舶重工集团公司第七○二研究所 | 应变传感器灵敏度系数的标定装置和方法 |
KR101376675B1 (ko) * | 2011-04-19 | 2014-03-20 | 광주과학기술원 | 이미징 및 운반 이중기능 나노입자-기반 백신 전달체 |
WO2012159121A2 (en) * | 2011-05-19 | 2012-11-22 | University Of Central Florida Research Foundation, Inc. | Microbe detection via hybridizing magnetic relaxation nanosensors |
WO2013012924A2 (en) | 2011-07-18 | 2013-01-24 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
MX345883B (es) | 2011-09-07 | 2017-02-22 | Midatech Ltd | Composiciones de peptidos en nanoparticulas. |
WO2013034741A1 (en) | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle tumour vaccines |
ES2856091T3 (es) | 2011-09-14 | 2021-09-27 | Univ Northwestern | Nanoconjugados capaces de atravesar la barrera hematoencefálica |
WO2013056092A1 (en) * | 2011-10-12 | 2013-04-18 | Case Western Reserve University | Multi-component nanochains |
TW201340996A (zh) * | 2012-03-12 | 2013-10-16 | Univ Nat Cheng Kung | 含鐵合金粒子在製備治療癌症之藥物的用途 |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
EP2935613B1 (en) * | 2012-12-19 | 2020-05-27 | DNAE Group Holdings Limited | Target capture system |
US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
US20140179941A1 (en) * | 2012-12-20 | 2014-06-26 | Board Of Trustees Of The University Of Alabama | Synthesis and Surface Functionalization of Particles |
GB201301991D0 (en) | 2013-02-05 | 2013-03-20 | Midatech Ltd | Permeation enhanced active-carrying nanoparticles |
GB201302427D0 (en) | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
GB201303787D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticle peptide compositions |
US10551379B2 (en) | 2013-03-15 | 2020-02-04 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
AU2014268603B2 (en) | 2013-05-21 | 2018-03-22 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
JP6697384B2 (ja) | 2013-07-25 | 2020-05-20 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 |
KR101536325B1 (ko) | 2013-10-16 | 2015-07-14 | 주식회사 지니스 | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 |
EP3912986B1 (en) | 2013-12-18 | 2023-12-13 | President and Fellows of Harvard College | Crp capture/detection of bacteria |
GB201401706D0 (en) | 2014-01-31 | 2014-03-19 | Midatech Ltd | Nanoparticle-insulin and insulin analogue compositions |
MX2016016507A (es) | 2014-06-12 | 2017-04-27 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
US9910035B1 (en) | 2014-07-16 | 2018-03-06 | Verily Life Sciences Llc | Polyvalent functionalized nanoparticle-based in vivo diagnostic system |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
CA2966215A1 (en) * | 2014-10-30 | 2016-05-06 | Sightline Innovation Inc. | System, method and apparatus for pathogen detection |
US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US10688125B2 (en) | 2014-12-23 | 2020-06-23 | Midatech Ltd. | Nanoparticles and their use in cancer therapy |
GB2541166A (en) | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
CN108289928A (zh) | 2015-08-06 | 2018-07-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
GB201701745D0 (en) | 2017-02-02 | 2017-03-22 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
AU2018255346B2 (en) | 2017-04-19 | 2024-05-02 | Capricor Inc | Methods and compositions for treating skeletal muscular dystrophy |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
US20190112731A1 (en) | 2017-10-12 | 2019-04-18 | Julianne Holloway | Manufacturing gradient materials using magnetically-assisted electrospinning |
WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
GB201819430D0 (en) | 2018-11-29 | 2019-01-16 | Midatech Ltd | Therapeutic compounds, nanoparticles and uses thereof |
GB201820470D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
GB201820471D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
WO2020148206A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity |
CN110470688B (zh) * | 2019-07-29 | 2021-07-13 | 华中农业大学 | 一种纳米螯合筛介导的低场核磁共振免疫传感器及其应用 |
WO2021123074A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Methods of sequencing by synthesis using a consecutive labeling scheme |
IT202000001048A1 (it) * | 2020-01-21 | 2021-07-21 | Univ Degli Studi Padova | Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici. |
IT202100001049A1 (it) * | 2021-01-21 | 2022-07-21 | Univ Degli Studi Padova | Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000504374A (ja) * | 1995-12-28 | 2000-04-11 | アール. ヒース,ジェイムズ | 有機的に官能価された金属の単分散微小結晶 |
WO2002032404A2 (en) * | 2000-10-16 | 2002-04-25 | Consejo Superior De Investigaciones Cientificas | Nanoparticles |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US87204A (en) * | 1869-02-23 | Improved velocipede | ||
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4662359A (en) * | 1983-08-12 | 1987-05-05 | Robert T. Gordon | Use of magnetic susceptibility probes in the treatment of cancer |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5260050A (en) * | 1988-09-29 | 1993-11-09 | Ranney David F | Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes |
GR1000686B (el) | 1989-11-16 | 1992-10-08 | Ortho Diagnostic Systems Inc | Μεθοδος παραγωγης ενος αντιδραστηριου κολλοειδους μεταλλου που περιεχει κολλοειδη τεμαχιδια μεταλλου με προκαθορισμενο μεγεθος. εθος. |
US6048897A (en) * | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
US5521289A (en) * | 1994-07-29 | 1996-05-28 | Nanoprobes, Inc. | Small organometallic probes |
RU2147243C1 (ru) * | 1994-09-27 | 2000-04-10 | Нюкомед Имагинг А/С | Контрастное средство |
AUPP008197A0 (en) * | 1997-10-29 | 1997-11-20 | Paragon Medical Limited | Improved targeted hysteresis hyperthermia as a method for treating diseased tissue |
EP1073902A2 (en) | 1998-04-20 | 2001-02-07 | University Of North Carolina At Chapel Hill | Nanometer particles containing a reactive monolayer |
DE19821968A1 (de) | 1998-05-18 | 1999-11-25 | Studiengesellschaft Kohle Mbh | Verfahren zur Modifizierung der Dispergiereigenschaften von metallorganisch-prästabilisierten bzw. -vorbehandelten Nanometallkolloiden |
WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
EP1031354A3 (en) * | 1999-01-19 | 2003-02-05 | Rohm And Haas Company | Polymeric MRI Contrast agents |
US6254662B1 (en) | 1999-07-26 | 2001-07-03 | International Business Machines Corporation | Chemical synthesis of monodisperse and magnetic alloy nanocrystal containing thin films |
US6767635B1 (en) | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
US6773823B2 (en) | 2000-04-07 | 2004-08-10 | University Of New Orleans Research And Technology Foundation, Inc. | Sequential synthesis of core-shell nanoparticles using reverse micelles |
US7132275B2 (en) | 2001-05-14 | 2006-11-07 | The John Hopkins University | Multifunctional magnetic nanowires |
US20030092029A1 (en) | 2001-06-06 | 2003-05-15 | Lee Josephson | Magneitc-nanoparticle conjugates and methods of use |
WO2003005029A2 (en) | 2001-07-03 | 2003-01-16 | Governors Of The University Of Alberta | Magnetic nanoparticles for bioseparation application and methods for producing same |
ATE519438T1 (de) * | 2001-09-26 | 2011-08-15 | Rice University | Optisch absorbierende nanopartikel für die verbesserte gewebereparatur |
FR2832671B1 (fr) * | 2001-11-23 | 2004-01-16 | Michelin Soc Tech | Disque de roue automobile, notamment pour vehicule de tourisme |
WO2003072830A1 (en) * | 2002-02-22 | 2003-09-04 | Purdue Research Foundation | Magnetic nanomaterials and methods for detection of biological materials |
WO2003086660A1 (en) * | 2002-04-09 | 2003-10-23 | The Government Of The United States Of America As Represented By The Secretary Of The Navy | Magnetic nanoparticles having passivated metallic cores |
CA2499318A1 (en) | 2002-09-18 | 2004-04-22 | Angela M. Belcher | Peptide mediated synthesis of metallic and magnetic materials |
-
2003
- 2003-06-09 GB GBGB0313259.4A patent/GB0313259D0/en not_active Ceased
-
2004
- 2004-06-07 DE DE602004030003T patent/DE602004030003D1/de active Active
- 2004-06-07 EP EP04736221A patent/EP1631318B1/en not_active Not-in-force
- 2004-06-07 JP JP2006516378A patent/JP5008977B2/ja not_active Expired - Fee Related
- 2004-06-07 DK DK04736221.5T patent/DK1631318T3/da active
- 2004-06-07 US US10/559,957 patent/US8557607B2/en not_active Expired - Fee Related
- 2004-06-07 CA CA2528460A patent/CA2528460C/en not_active Expired - Fee Related
- 2004-06-07 EP EP12167788.4A patent/EP2486944B1/en not_active Not-in-force
- 2004-06-07 ES ES04736221T patent/ES2355728T3/es active Active
- 2004-06-07 ES ES10009913T patent/ES2401957T3/es active Active
- 2004-06-07 AU AU2004244811A patent/AU2004244811B9/en not_active Ceased
- 2004-06-07 ES ES12167788.4T patent/ES2441235T3/es active Active
- 2004-06-07 AT AT04736221T patent/ATE487496T1/de active
- 2004-06-07 WO PCT/GB2004/002408 patent/WO2004108165A2/en active Search and Examination
- 2004-06-07 EP EP10009913A patent/EP2277548B1/en not_active Not-in-force
-
2012
- 2012-09-13 HK HK12109012.1A patent/HK1168051A1/xx not_active IP Right Cessation
-
2013
- 2013-10-02 US US14/044,113 patent/US20140107738A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000504374A (ja) * | 1995-12-28 | 2000-04-11 | アール. ヒース,ジェイムズ | 有機的に官能価された金属の単分散微小結晶 |
WO2002032404A2 (en) * | 2000-10-16 | 2002-04-25 | Consejo Superior De Investigaciones Cientificas | Nanoparticles |
JP2004511511A (ja) * | 2000-10-16 | 2004-04-15 | コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカス | ナノ粒子 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010517287A (ja) * | 2007-01-24 | 2010-05-20 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 作用領域の磁性粒子に影響を与え及び/又はそれらを検出する方法、磁性粒子及び磁性粒子の使用 |
JP2013505728A (ja) * | 2009-09-25 | 2013-02-21 | エヌ3ディー バイオサイエンスィズ,インコーポレイテッド | 細胞を磁性化するための材料及び磁気操作 |
JP2015518874A (ja) * | 2012-06-08 | 2015-07-06 | エスリス ゲーエムベーハーethris GmbH | メッセンジャーrnaの肺送達 |
Also Published As
Publication number | Publication date |
---|---|
US8557607B2 (en) | 2013-10-15 |
AU2004244811B9 (en) | 2008-04-24 |
ES2441235T3 (es) | 2014-02-03 |
WO2004108165A2 (en) | 2004-12-16 |
CA2528460C (en) | 2012-10-30 |
EP1631318A2 (en) | 2006-03-08 |
ES2401957T3 (es) | 2013-04-25 |
EP2277548A3 (en) | 2011-04-27 |
ES2355728T3 (es) | 2011-03-30 |
EP2277548B1 (en) | 2013-01-16 |
AU2004244811B2 (en) | 2008-02-07 |
GB0313259D0 (en) | 2003-07-16 |
DK1631318T3 (da) | 2011-02-21 |
CA2528460A1 (en) | 2004-12-16 |
DE602004030003D1 (de) | 2010-12-23 |
EP1631318B1 (en) | 2010-11-10 |
HK1168051A1 (en) | 2012-12-21 |
US20060233712A1 (en) | 2006-10-19 |
US20140107738A1 (en) | 2014-04-17 |
EP2486944A1 (en) | 2012-08-15 |
WO2004108165A3 (en) | 2005-06-16 |
ATE487496T1 (de) | 2010-11-15 |
AU2004244811A1 (en) | 2004-12-16 |
EP2277548A2 (en) | 2011-01-26 |
EP2486944B1 (en) | 2013-12-04 |
JP5008977B2 (ja) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5008977B2 (ja) | 磁性ナノ粒子 | |
Zarschler et al. | Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications | |
Yen et al. | Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery | |
Chen et al. | Nanoparticles for improving cancer diagnosis | |
Vivero-Escoto et al. | Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications | |
KR100924786B1 (ko) | 진단 및 치료용 자성 메탈 나노 복합체 | |
Bárcena et al. | Applications of magnetic nanoparticles in biomedicine | |
Soufi et al. | Eco-friendly and sustainable synthesis of biocompatible nanomaterials for diagnostic imaging: current challenges and future perspectives | |
Cormode et al. | Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality | |
US20030228260A1 (en) | Particulate agents | |
Zhang et al. | Superparamagnetic iron oxide nanoparticles for MR imaging of pancreatic cancer: Potential for early diagnosis through targeted strategies | |
Chen | Nanoplatform-based molecular imaging | |
JP2009114066A (ja) | 機能性分子が導入された有機磁性ナノ複合体 | |
IT202000028445A1 (it) | Nanosistema per la diagnosi ed il trattamento fototermico di tumori | |
Zheng et al. | Recent advances in superparamagnetic iron oxide based nanoprobes as multifunctional theranostic agents for breast cancer imaging and therapy | |
Yadav et al. | Inorganic nanobiomaterials for medical imaging | |
KR101233439B1 (ko) | 파이렌 고분자를 이용한 자극 감응형 자성 나노복합체 및 상기 나노복합체를 포함하는 조영제 조성물 | |
AU2008202025B2 (en) | Magnetic nanoparticles | |
Penadés et al. | Magnetic nanoparticles | |
Ghalandarlaki et al. | In vitro evaluation of gadolinium-silica mesoporous nanoparticles-monoclonal antibody: Potential nanoprobe for prostate cancer cell imaging | |
Efthimiadou et al. | Molecular Targets and Optical Probes | |
Priya et al. | Revolutionizing Imaging and Diagnostics: Harnessing Metallic Nanoparticles and Nanocarriers for Cutting-Edge Theranostics | |
Wu et al. | Combinatorial Nanoparticles and Their Applications in Biomedicine | |
Sardan et al. | Advances in Nanoparticle‐Based Medical Diagnostic and Therapeutic Techniques | |
Singh et al. | Nanocarriers in Early Diagnosis of Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120127 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120315 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120501 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5008977 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |